Visiomed Group SA (ALVMG.PA)

ALVMG.PA on Paris Stock Exchange

3.45EUR
22 May 2015
Change (% chg)

€0.01 (+0.29%)
Prev Close
€3.44
Open
€3.42
Day's High
€3.49
Day's Low
€3.39
Volume
12,476
Avg. Vol
105,177
52-wk High
€7.28
52-wk Low
€1.84

ALVMG.PA

Chart for ALVMG.PA

About

Visiomed Group SA is a France-based company specialized in designing, developing, manufacturing, and selling medical materials. The Company's product portfolio comprises non-contact infrared thermometers (ThermoFlash brand), automatic blood pressure meters (ThermoFlash and OXYcheck), pain treatment devices using electrotherapy... (more)

Overall

Beta: -0.09
Market Cap(Mil.): €21.05
Shares Outstanding(Mil.): 6.10
Dividend: --
Yield (%): --

Financials

  ALVMG.PA Industry Sector
P/E (TTM): -- 38.87 39.17
EPS (TTM): -0.88 -- --
ROI: -52.64 11.34 15.58
ROE: -76.76 13.34 16.57
Search Stocks

BRIEF-Visiomed Group Q1 revenue of 3.5 million euros, up 25 pct

* FY 2014 net loss of 2.6 million euros ($2.90 million) versus loss of 2.6 million euros a year ago

30 Apr 2015

BRIEF-Visiomed Group's BewellConnect launches MyGluco

* BewellConnect brand launches connected blood sugar reader called MyGluco

07 Apr 2015

BRIEF-Visiomed Group's Bewellconnect brand launches MyECG

* Says it's Bewellconnect brand launches MyECG, a miniture wireless electrocardiogram Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Mar 2015

BRIEF-Visiomed Group signs distribution agreements

* Signs distribution agreements in Maghreb, Australia, Canada, Middle East and Africa Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

09 Feb 2015

BRIEF-Visiomed Group issues 1.6 mln new ordinary shares - Euronext

* Reason for Visiomed Group capital increase is private placement

28 Jan 2015

BRIEF-Visiomed FY revenue rises to 13.32 mln euros, up 18 pct

* FY revenue of 13.32 million euros ($15.7 million) versus 11.27 million euros, up 18 percent

08 Jan 2015

BRIEF-Visiomed Group announces FDA approval for Thermoflash products

* Announces that all Thermoflash products received FDA approval in addition to the CE mark and registration with the ANSM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

23 Dec 2014

BRIEF-Visiomed Group announces collaboration with Orange

* Announces collaboration with Orange to create Myhealthbox, a telemedicine solution

15 Dec 2014

BRIEF-Visiomed announces 3 commands for 45,000 Thermoflash thermometers

* Announces 3 commands for 45,000 Thermoflash thermometers in total

08 Dec 2014

BRIEF-Visiomed group wins contract in Africa and licence agreement

* Wins major contract in Africa and signs brand license agreement

03 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks